AAV9.45 Serotype
Liver-detargeted AAV9 variant engineered to reduce hepatic uptake while maintaining cardiac and skeletal muscle transduction.
| Tropism | Cardiac muscle, skeletal muscle (reduced liver) |
|---|
Characteristics
5-fold reduction in liver uptake versus AAV9. Maintained cardiac and skeletal muscle transduction efficiency. Rational mutagenesis approach. Improved therapeutic index for muscle-targeted applications.
Applications
Cardiac gene therapy with reduced liver exposure. Muscular dystrophies. Systemic muscle-directed gene delivery.
Sequence1 bp
Sign in to view the full sequence.
Sign inReferences
- 1.Pulicherla et al. (2011). Engineering liver-detargeted AAV9 vectors for cardiac and musculoskeletal gene transfer. Mol Ther — Pulicherla 2011 AAV9 Variants
